Want to see AU:HMD full AI Analyst Report?
HMD Stock Chart & Stats
AU$0.04
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.04
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.02 - AU$0.06
Previous CloseN/A
Volume370.09K
Average Volume (3M)1.96M
Market Cap
AU$39.39M
Enterprise ValueAU$19.93M
Total Cash (Recent Filing)AU$914.65K
Total Debt (Recent Filing)AU$282.39K
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Aug 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding1,158,636,600
10 Day Avg. Volume1,195,844
30 Day Avg. Volume1,958,766
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)41.38
Price to Sales (P/S)131.32
P/FCF Ratio-10.53
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Gross MarginsA sustained recovery in gross margin to roughly 60% indicates the core product/device economics can support higher unit profitability. Over 2–6 months this suggests the company has pricing or cost advantages at the product level, creating a clearer path to operating leverage if SG&A is controlled.
Debt-free Balance SheetZero reported debt and a positive equity position reduce immediate solvency and interest burden risks, giving strategic flexibility. This lower financial leverage supports the company’s ability to manage runway, pursue partnerships, or raise non-debt capital with less refinancing pressure.
Niche Digital Maternal/fetal Health PlatformA focused product set in maternal and fetal remote monitoring aligns with secular telehealth and home-care trends, offering potential recurring device/software revenue and clinical stickiness. Specialization supports differentiation and pathway to deeper clinical partnerships over time.
Bears Say
Persistent Negative Operating And Free Cash FlowConsistent negative operating and free cash flow creates ongoing funding requirements and increases liquidity risk. Over months this forces reliance on external financing or equity dilution and limits the company’s ability to invest in scaling sales, R&D, or commercial expansion without fresh capital.
Ongoing Net Losses And Weak ProfitabilityDeep and persistent operating losses undermine return metrics and erode shareholder equity, constraining reinvestment and strategic options. Without sustained operating profit, the business will struggle to self-fund growth and may face repeated dilutive raises or cost-cutting that impair long-term competitiveness.
Revenue Volatility And Recent ContractionVolatile and contracting revenue reduces scale benefits and delays absorption of fixed costs, making margin improvements harder to convert into net profitability. Over a multi-month horizon this raises execution risk for commercial adoption and increases the urgency of securing sustainable demand channels.
HeraMED Ltd. News
HMD FAQ
What was HeraMED Ltd.’s price range in the past 12 months?
HeraMED Ltd. lowest share price was AU$0.02 and its highest was AU$0.06 in the past 12 months.
What is HeraMED Ltd.’s market cap?
HeraMED Ltd.’s market cap is AU$39.39M.
When is HeraMED Ltd.’s upcoming earnings report date?
HeraMED Ltd.’s upcoming earnings report date is Aug 21, 2026 which is in 9 days.
How were HeraMED Ltd.’s earnings last quarter?
HeraMED Ltd. released its earnings results on Feb 26, 2026. The company reported -AU$0.002 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.002.
Is HeraMED Ltd. overvalued?
According to Wall Street analysts HeraMED Ltd.’s price is currently Overvalued.
Does HeraMED Ltd. pay dividends?
HeraMED Ltd. does not currently pay dividends.
What is HeraMED Ltd.’s EPS estimate?
HeraMED Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does HeraMED Ltd. have?
HeraMED Ltd. has 1,158,636,600 shares outstanding.
What happened to HeraMED Ltd.’s price movement after its last earnings report?
HeraMED Ltd. reported an EPS of -AU$0.002 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 5.556%.
Which hedge fund is a major shareholder of HeraMED Ltd.?
Currently, no hedge funds are holding shares in AU:HMD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
HeraMED Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
―
20 days / 200 days
Momentum
100.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-68.43%
Trailing 12-Months
Company Description
HeraMED Ltd.
HeraMED Ltd. (HMD) is a digital health company focused on maternal and fetal health. The company develops technology intended to support pregnancy monitoring and maternity care through connected devices and software, including solutions designed for remote/at-home monitoring and clinical decision support. null
Technical Analysis
Compumedics Limited
―
Impedimed Limited
―
Uscom Limited
―
Atomo Diagnostics Ltd.
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―